Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Total Current Liabilities (2016 - 2025)

Acro Biomedical has reported Total Current Liabilities over the past 10 years, most recently at $401062.0 for Q4 2025.

  • Quarterly results put Total Current Liabilities at $401062.0 for Q4 2025, up 22.67% from a year ago — trailing twelve months through Dec 2025 was $401062.0 (up 22.67% YoY), and the annual figure for FY2025 was $401062.0, up 22.67%.
  • Total Current Liabilities for Q4 2025 was $401062.0 at Acro Biomedical, down from $436942.0 in the prior quarter.
  • Over the last five years, Total Current Liabilities for ACBM hit a ceiling of $436942.0 in Q3 2025 and a floor of $60158.0 in Q2 2021.
  • Median Total Current Liabilities over the past 5 years was $273607.5 (2023), compared with a mean of $239881.0.
  • Biggest five-year swings in Total Current Liabilities: plummeted 78.71% in 2022 and later soared 272.83% in 2023.
  • Acro Biomedical's Total Current Liabilities stood at $91651.0 in 2021, then soared by 119.44% to $201116.0 in 2022, then soared by 43.49% to $288575.0 in 2023, then rose by 13.3% to $326946.0 in 2024, then grew by 22.67% to $401062.0 in 2025.
  • The last three reported values for Total Current Liabilities were $401062.0 (Q4 2025), $436942.0 (Q3 2025), and $370797.0 (Q2 2025) per Business Quant data.